NCT00290537View on ClinicalTrials.gov

Phase II Study of ZD6474 in Advanced NSCLC

PHASE2TerminatedINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

January 31, 2006

Primary Completion Date

April 30, 2008

Study Completion Date

April 30, 2008

Conditions
Lung Cancer
Interventions
DRUG

ZD6474

ZD6474 alone: Cycles 1-3 = 300 mg PO Daily x 3 Weeks; ZD6474+Carboplatin+Paclitaxel = 300 mg oral (PO) Daily or 100 mg PO Daily plus Carboplatin and Paclitaxel Every 3 Weeks.

DRUG

Carboplatin

6 AUC IV Over 15-30 Minutes, Immediately After Paclitaxel

DRUG

Paclitaxel

200 mg/m\^2 IV Over 3 Hours On Day 1

Trial Locations (1)

77030

University of Texas M.D.Anderson Cancer Center, Houston

Sponsors

Collaborators (1)

AstraZeneca
All Listed Sponsors
collaborator

AstraZeneca

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER